1. A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in Patients With Advanced Cancer: A Placebo-Controlled, Proof-of-Concept Trial 
Sharon M. Weinstein, MD, Amy P. Abernethy, MD, Susan E. Spruill, PStat, MS, Isadore M. Pike, MD, Andrea True Kelly, PhD, Linda G. Jett, MSN 
Journal of Pain and Symptom Management 
Volume 43, Issue 4, Pages (April 2012)
DOI: /j.jpainsymman
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1 Schematic of dose escalation and treatment decisions.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2 CONSORT diagram of patient disposition in the study.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Absolute change in NRS scores for each patient by treatment group. (Total number of NRS weekly scores per patient [up to 11] cannot be ascertained in this figure as duplicate scores are not depicted, with the exception that a score [only 1] that overlays baseline and/or end point is visible.)
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Maximum reduction in neuropathic pain score by patient ordered from greatest to least within treatment group. (P=0.02 obtained from a Wilcoxon rank sum test.)
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5
Correlation of weekly diary and clinic NRS scores for all subjects. (Diary scores are plotted as the mean of the first six daily NRS scores after each weekly visit.)
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions